Blood Testing Market Report Scope & Overview:

The Blood Testing Market was valued at USD 104.24 Billion in 2025 and is expected to reach USD 217.19 Billion by 2035, growing at a CAGR of 7.61% from 2026-2035.

Blood testing encompasses the full range of diagnostic procedures performed on blood samples, spanning routine glucose and complete blood count panels run in every hospital laboratory through specialised infectious disease, coagulation, and biomarker assays. The category sits at core of modern clinical medicine, since blood remains the single most accessible and information-rich diagnostic sample a physician can draw from a patient. Growth is supported by the growing burden of chronic and infectious diseases requiring regular diagnostic monitoring, rising global health awareness, and continued automation. Novel blood-based biomarker tests, capable of detecting conditions including Alzheimer's disease and cardiovascular risk from a simple blood draw, continue to widen the diagnostic reach of blood testing beyond its traditional metabolic and infectious disease applications.

In 2025, Roche Diagnostics launched the Elecsys pTau181 assay, the only blood-based biomarker test indicated as an aid in the initial assessment for Alzheimer's disease and other causes of cognitive decline in the primary-care setting, alongside the first FDA-cleared blood test measuring Lipoprotein(a) in molar units to help assess cardiovascular risk, both reflecting the company's broader push to bring sophisticated diagnostic capability closer to the point of patient care.

Blood Testing Market Trends

• Rising adoption of blood-based biomarker tests for neurological and cardiovascular risk assessment.
• Growing automation of laboratory testing workflows improving throughput and reducing turnaround time.
• Expanding companion diagnostic development linking blood tests directly to targeted drug therapies.
• Increasing point-of-care blood testing adoption bringing diagnostics closer to outpatient and home settings.
• Rising merger and acquisition activity consolidating diagnostics and testing laboratory service providers.
• Growing regulatory clearance activity for novel assays addressing previously underserved diagnostic needs.

U.S. Blood Testing Market Overview

The U.S. Blood Testing Market was valued at USD 30.56 Billion in 2025 and is expected to reach USD 59.28 Billion by 2035, growing at a CAGR of 6.85% from 2026-2035.

The U.S. Blood Testing Market benefits from a vast clinical laboratory infrastructure performing more than seven billion blood tests annually, broad insurance coverage supporting routine and specialised diagnostic testing, and the presence of leading diagnostics manufacturers headquartered in the country that continue to compete on assay innovation and automation. Rising chronic disease prevalence, spanning diabetes, cardiovascular conditions, and cancer, continues to drive frequent diagnostic testing and monitoring requirements across the population. Leading manufacturers continue to secure regulatory clearances for novel assays addressing previously underserved diagnostic needs, from companion diagnostics supporting targeted drug therapies through blood-based biomarker tests for neurological conditions. Continued consolidation among diagnostics companies, combined with sustained innovation in automated testing platforms, is expected to support strong demand growth throughout the forecast period.

On November 19, 2025, Abbott Laboratories entered into a definitive agreement to acquire Exact Sciences, a leading provider of cancer screening and diagnostic tests, in a transaction the company expects will strengthen its diagnostics segment and expand its blood-based and molecular testing portfolio across oncology applications.

Blood Testing Market Segment Analysis

• By Test Type, the Glucose Testing segment dominated the market with a 17.85% share in 2025, while the Glucose Testing segment is the fastest growing with a CAGR of 8.95% during 2026-2035.
• By Product, the Reagents and Kits segment dominated the market with a 41.60% share in 2025, while the Instruments segment is the fastest growing with a CAGR of 8.35% during 2026-2035.
• By Method, the Automated segment dominated the market with a 64.75% share in 2025, while the Automated segment is the fastest growing with a CAGR of 9.45% during 2026-2035.
• By End Use, the Hospitals and Clinics segment dominated the market with a 43.60% share in 2025, while the Diagnostic Laboratories segment is the fastest growing with a CAGR of 8.65% during 2026-2035.

By Test Type, Glucose Testing Dominates the Market and Glucose Testing Grows Fastest

Glucose testing dominated the market in 2025. The sheer global scale of diabetes diagnosis and ongoing management continues to anchor glucose testing as the largest single test type category, reflecting the enormous and still-growing diabetic patient population requiring frequent blood glucose monitoring across both clinical and home settings worldwide.

Glucose testing is also expected to grow fastest over the forecast period, as rising global diabetes prevalence continues to reinforce this test type's already dominant position, supported by expanding screening programs and growing at-risk population awareness driving earlier diagnosis and more frequent ongoing monitoring across both developed and emerging healthcare markets.

By Product, Reagents and Kits Dominates the Market and Instruments Grows Fastest

Reagents and kits dominated the market in 2025. These consumable products continue to generate reliable, recurring revenue tied directly to actual testing volume, and the sheer scale of global blood test throughput continues to anchor reagents and kits as the largest product category across the broader blood testing market.

Instruments are projected to be the fastest-growing product category over the forecast period, as continued laboratory automation investment and capacity expansion drive sustained demand for advanced analysers capable of processing rising test volumes with improved accuracy, speed, and reduced labour requirements relative to legacy laboratory equipment nearing replacement.

By Method, Automated Dominates the Market and Automated Grows Fastest

Automated testing dominated the market in 2025. Modern clinical laboratories increasingly rely on automated platforms to process the overwhelming majority of routine blood tests, delivering faster turnaround times and reduced manual error relative to older manual testing approaches, sustaining automated testing's position as the clear leading method category.

Automated testing is also expected to grow fastest over the forecast period, as rising overall test volumes and persistent laboratory staffing constraints continue to push facilities toward automation. Continued advancement in automated analyser capability keeps reinforcing this method's already dominant position relative to manual testing, which remains confined to niche, resource-limited applications.

By End Use, Hospitals and Clinics Dominates the Market and Diagnostic Laboratories Grows Fastest

Hospitals and clinics dominated the market in 2025. The continuous, high-volume blood testing these facilities perform across emergency, inpatient, and outpatient settings continues to anchor hospitals and clinics as the largest end-use category across the broader blood testing market by a considerable margin over every alternative setting.

Diagnostic laboratories are projected to be the fastest-growing end-use category over the forecast period, as rising outsourcing of laboratory testing to specialised reference laboratories continues to expand demand for centralised, high-throughput testing capacity capable of serving multiple hospital and physician office customers without each maintaining extensive in-house capability.

Regional Analysis

North America Blood Testing Market Insights

North America dominated the global Blood Testing Market with a 34.65% share in 2025, supported by its extensive clinical laboratory infrastructure, broad healthcare coverage, advanced diagnostic capabilities, and concentration of leading diagnostics manufacturers. The United States represents the largest contributor within the region, driven by high demand for blood-based diagnostic testing, advanced healthcare facilities, and widespread adoption of automated laboratory systems. Strong investments in diagnostic technologies, laboratory automation, and point-of-care testing further reinforce regional market leadership across major test types and product categories.

Canada contributes additional regional demand through its publicly funded healthcare system and expanding diagnostic testing infrastructure. Continued consolidation across the diagnostics industry, increasing adoption of automated testing platforms, and investments in advanced laboratory technologies are expected to sustain North America’s leading position throughout the forecast period, despite comparatively faster growth in emerging Asia Pacific markets.

Asia Pacific Blood Testing Market Insights

Asia Pacific is projected to be the fastest-growing region in the global Blood Testing Market during the forecast period, registering a CAGR of approximately 9.85%. Rapid expansion of hospital infrastructure, increasing prevalence of chronic diseases, rising healthcare expenditure, and growing government investment in healthcare systems are accelerating the adoption of blood testing services across the region. China represents the largest contributor to regional demand, supported by its expanding hospital network, growing patient population, and strengthening domestic diagnostics manufacturing capabilities.

India is also contributing to the growth of the market owing to increased availability of healthcare services, better diagnostic facilities, and rising awareness regarding preventive tests. Japan and South Korea also add demand to the market due to their developed healthcare system, well-established clinical laboratories, and technological diagnostic solutions. Continued healthcare modernization, increasing diagnostic testing volumes, and investments in laboratory automation are expected to further strengthen Asia Pacific’s position as the fastest-growing regional market.

Europe Blood Testing Market Insights

Europe holds a significant share of the global Blood Testing Market, supported by Germany’s substantial healthcare sector, advanced medical infrastructure, and the region’s mature and well-regulated diagnostics industry. Comprehensive public health insurance frameworks across European countries continue to support consistent demand for blood testing services across major test types and applications. Germany represents a leading regional contributor due to its extensive healthcare network, established clinical laboratory infrastructure, and strong adoption of advanced diagnostic technologies.

The United Kingdom, France, and Italy also offer demand for the region through the continued expansion of access to diagnostic tests within the healthcare system of each country. Increased spending on laboratory automation and digital diagnostics has also aided in driving growth in the market. Continued healthcare modernization and technological adoption are expected to sustain steady growth across the broader European Blood Testing Market throughout the forecast period, despite comparatively faster expansion in emerging regions.

MEA and Latin America Blood Testing Market Insights

The Middle East and Africa (MEA) region is experiencing continued growth in the Blood Testing Market due to investments made towards improving healthcare infrastructure in the UAE and Saudi Arabia. Modernizing health care efforts by governments have been geared towards increasing hospital facilities as well as advanced testing services and laboratories, thereby providing greater opportunities for blood testing products. Other GCC countries are also beginning to improve on their healthcare facilities and diagnostic capabilities.

The Latin American market is dominated by Brazil because the domestic healthcare industry, developing hospitals, and increasing demand for diagnostics are driving factors there. Mexico adds further growth opportunities because the healthcare sector is becoming more accessible and diagnostics are continuously growing there. Higher spending on healthcare, improved awareness about preventive diagnostics, and developing laboratories infrastructure will be the driving forces in both regions. However, growth remains comparatively moderate due to variations in healthcare access, infrastructure, and diagnostic adoption across individual countries.

Market Dynamics

Growth Drivers: Chronic Disease Burden and Testing Automation

Increasing incidence of both chronic and infectious diseases is one of the key drivers for the Blood Testing Market, owing to the rising incidences of diseases such as diabetes, cardiovascular ailments, cancers, and infectious diseases that require blood test for diagnosis and ongoing monitoring. Aging population serves to be an additional driver for the market due to the increased health testing among the elderly population. Another major driver for the market is the automation of laboratories due to which laboratories can conduct higher volume of tests with greater accuracy and precision.

Increased health care spending along with growing diagnostic infrastructure in emerging markets is another factor that is aiding growth in the market. Increased awareness regarding preventive health care is promoting health check-ups among individuals to detect diseases at an early stage. With increased individuals opting for regular blood tests for their health care needs, the addressable patient pool for blood testing is expanding.

Restraints: High Device Cost and Reimbursement Complexity

The high expense of blood testing kits and sophisticated laboratory equipment is still one such constraint, especially in emerging and underdeveloped health care markets, where financial constraints could prevent investing in complex diagnostic technologies. The cost of acquiring advanced automated analyzers, molecular testing systems, and biomarker-based testing kits can be quite high along with maintenance and labor expenses. This can slow adoption compared with simpler and lower-cost conventional testing technologies.

The issue of reimbursement complexity is another significant issue since the policies regarding reimbursement for novel blood-based tests differ significantly among different countries and regions. Lack of reimbursement coverage may limit patient access to these services and also prevent healthcare professionals from using new diagnostic methods. Variation in reimbursement guidelines, regulations, and healthcare system financing is another factor that contributes to market fragmentation. This will also affect the commercialization process of innovative testing methods.

Opportunities: Novel Biomarker Development and Point-of-Care Expansion

The evolution of novel biomarkers based on the blood holds immense potential for the Blood Testing Market, especially as advances in diagnostics facilitate the early detection and diagnosis of difficult to diagnose diseases. The firms that develop proprietary biomarker tests for cancer, cardiovascular diseases, neurological disorders, and many more complicated diseases may be able to capitalize on the premium demand for better diagnostics. Increasing investment in precision medicine and personalized healthcare is further encouraging development of targeted blood-based testing solutions.

Point of Care testing is another area which offers substantial growth potential due to the advances made in rapid diagnostic testing where it becomes possible to carry out tests outside centralized labs. Portable and user-friendly blood test systems will be useful for use in clinics, emergency units, pharmacies, remote locations, and even home testing. The increasing inclination towards quick diagnosis and decentralized delivery of healthcare along with convenient testing will offer more chances for companies in this field.

Recent Developments:

• 2026: F. Hoffmann-La Roche Ltd. expanded U.S. blood-testing capabilities through continued development of advanced molecular and immunodiagnostic platforms, supporting faster, automated testing and broader clinical laboratory applications.
• 2026: Siemens Healthineers AG launched the Innovance D-Dimer 2.0 assay in the U.S. after FDA 510(k) clearance, supporting rapid blood-clot assessment and streamlined coagulation testing workflows.
• 2026: Becton, Dickinson and Company expanded blood-testing capabilities through continued development of automated specimen-management and diagnostic solutions, supporting laboratory efficiency, standardized workflows, and increasing clinical testing volumes.

Blood Testing Market Key Players are:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• Danaher Corporation (Beckman Coulter)
• Becton, Dickinson and Company
• Thermo Fisher Scientific Inc.
• bioMerieux SA
• Sysmex Corporation
• QuidelOrtho Corporation
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings
• Bio-Rad Laboratories, Inc.
• Revvity, Inc.
• Grifols S.A.
• Agilent Technologies, Inc.
• Sekisui Diagnostics
• Randox Laboratories Ltd.
• EKF Diagnostics Holdings plc
• Trinity Biotech plc
• Mindray Medical International Limited

Blood Testing Market Report Scope :